Valeant Falls After CFO Warns About Possible 'Surprises'

The transcript discusses the unexpected statement by the CFO during an earnings call, which led to investor concerns. The company is facing challenges, including issues with the Salix business and dermatology sales. Despite these, there are positive aspects like a high sales force retention rate and plans to sell assets. Michael Pearson remains a consultant with limited involvement. The transcript also touches on investor dynamics, particularly Bill Ackman's continued support and Carl Icahn's challenges.

What is Michael Pearson's current role with Valiant?

What challenges are Bill Ackman and Carl Icahn facing with their investments?